Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

He Cheng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4807-9614; OpenAlex author ID A5143544625. Sources: OpenAlex.

Their work

Papers
34 (first author 3, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
40
Papers, trials and grants by year

2015: 1 paper · 2016: 3 papers · 2017: 3 papers · 2018: 4 papers · 2019: 3 papers · 2020: 5 papers · 2021: 2 papers · 2022: 4 papers · 2023: 4 papers · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 34

  1. Comparative evaluation of chemotherapy and CAR-T cell therapy in genetically engineered self-sustaining primary pancreatic cancer organoids. Last author DOI 10.1016/j.pan.2026.07.013↗
  2. Corrigendum to "Wang X, Wang R, Lin X et al. Comparative evaluation of chemotherapy and CAR-T cell therapy in genetically engineered self-sustaining primary pa… Last author DOI 10.1016/j.pan.2026.09.001↗
  3. Assessment of tertiary lymphoid structures via 18F-FDG PET/CT scan in patients with pancreatic adenocarcinoma. Last author DOI 10.1007/s00262-025-04205-x↗
  4. Ectopic CXCR2 expression cells improve the anti-tumor efficiency of CAR-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00262-024-03648-y↗
  5. Antigen/HLA-agnostic strategies for Characterizing Tumor-responsive T cell receptors in PDAC patients via single-cell sequencing and autologous organoid applic… Co-author DOI 10.1016/j.canlet.2024.216741↗
  6. Laparoscopic pancreaticoduodenectomy with portal or superior mesenteric vein resection and reconstruction for pancreatic cancer: A single-center experience. First author DOI 10.1016/j.hbpd.2023.01.004↗
  7. Characterization of intratumoral tertiary lymphoid structures in pancreatic ductal adenocarcinoma: cellular properties and prognostic significance. Co-author DOI 10.1136/jitc-2023-006698↗
  8. A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma. Last author DOI 10.1186/s12876-023-02748-w↗
  9. Characterization of Estrogen Receptors in Pancreatic Adenocarcinoma with Tertiary Lymphoid Structures. Co-author DOI 10.3390/cancers15030828↗
  10. Influence of continuing nursing care team mode on the rehabilitation of patients with pancreatic cancer after postoperative daily chemotherapy. Co-author DOI 10.1007/s00520-022-07308-8↗
  11. Aberrant APOBEC3C expression induces characteristic genomic instability in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41389-022-00411-9↗
  12. Atypical Mucin Expression Predicts Worse Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2022/7353572↗
  13. TGF-β1-induced RAP2 regulates invasion in pancreatic cancer. Co-author DOI 10.3724/abbs.2022015↗
  14. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter. Co-author DOI 10.1016/j.bbcan.2020.188409↗
  15. High GFPT1 expression predicts unfavorable outcomes in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12957-021-02147-z↗
  16. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients. Co-author DOI 10.1002/cam4.2895↗
  17. Prior history of acute pancreatitis predicts poor survival in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.02.016↗
  18. Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy. First author DOI 10.1177/1073274820915947↗
  19. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-020-00958-3↗
  20. Prognostic Value of the C-Reactive Protein/Lymphocyte Ratio in Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08301-3↗
  21. Kras G12D mutation contributes to regulatory T cell conversion through activation of the MEK/ERK pathway in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.01.013↗
  22. Characteristics and Outcomes of Pancreatic Cancer by Histological Subtypes. Co-author DOI 10.1097/mpa.0000000000001338↗
  23. The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer. Co-author DOI 10.2147/cmar.s211363↗
  24. MUC16 C terminal-induced secretion of tumor-derived IL-6 contributes to tumor-associated Treg enrichment in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2018.01.017↗
  25. New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.08.003↗
  26. Application of the Eighth Edition of the American Joint Committee on Cancer Staging for Pancreatic Adenocarcinoma. First author DOI 10.1097/mpa.0000000000001073↗
  27. Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions. Co-author DOI 10.1186/s13045-017-0551-7↗
  28. CA19-9-Low&Lewis (+) pancreatic cancer: A unique subtype. Co-author DOI 10.1016/j.canlet.2016.10.046↗
  29. Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000001741↗
  30. Patients with normal-range CA19-9 levels represent a distinct subgroup of pancreatic cancer patients. Co-author DOI 10.3892/ol.2016.5501↗
  31. The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients. Co-author DOI 10.1016/j.pan.2016.09.007↗
  32. Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping. Co-author DOI 10.1016/j.pan.2016.09.013↗
  33. The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer. Co-author DOI 10.3390/ijms17071090↗
  34. Epithelial-mesenchymal transition in pancreatic cancer: Is it a clinically significant factor? Co-author DOI 10.1016/j.bbcan.2014.11.004↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 33 shared papers, 2015–2026 · strength 4.04
  2. Chen Liu · 29 shared papers, 2016–2026 · strength 3.45
  3. Guopei Luo · 22 shared papers, 2016–2022 · strength 1.96
  4. Kaizhou Jin · 21 shared papers, 2016–2022 · strength 1.85
  5. Yusheng Chen · 9 shared papers, 2022–2025 · strength 1.63
  6. Xuan Lin · 8 shared papers, 2022–2025 · strength 1.39
  7. Xuan Zou · 8 shared papers, 2022–2025 · strength 1.39
  8. Yitao Gong · 11 shared papers, 2019–2022 · strength 1.23
  9. Xu Wang · 7 shared papers, 2022–2025 · strength 1.20
  10. Mingjian Ma · 6 shared papers, 2023–2025 · strength 1.19
  11. Quanxing Ni · 14 shared papers, 2016–2021 · strength 1.18
  12. Zhiyao Fan · 12 shared papers, 2018–2021 · strength 1.15
  13. Yunzhen Qian · 9 shared papers, 2020–2023 · strength 1.11
  14. Yesiboli Tasiheng · 6 shared papers, 2022–2024 · strength 0.97
  15. Zhengjie Dai · 6 shared papers, 2022–2024 · strength 0.97
  16. Chao Yang · 8 shared papers, 2018–2020 · strength 0.67
  17. Jin Xu · 9 shared papers, 2015–2020 · strength 0.60
  18. Chen Liu · 4 shared papers, 2015–2024 · strength 0.60
  19. Yu Yan · 3 shared papers, 2023–2025 · strength 0.56
  20. Jiang Long · 9 shared papers, 2015–2018 · strength 0.54
  21. Xu Wang · 2 shared papers, 2026 · strength 0.51
  22. Meng Guo · 8 shared papers, 2016–2018 · strength 0.49
  23. Liang Liu · 7 shared papers, 2015–2018 · strength 0.40
  24. Kun Fan · 4 shared papers, 2018–2019 · strength 0.33
  25. Yu Liu · 2 shared papers, 2021–2023 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.